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Abstract
Background: Cluster headache (CH) is the most frequent trigemino-autonomic cephalgia. CH can manifest as
episodic (ECH) or chronic cluster headache (CCH) causing significant burden of disease and requiring attack therapy
and prophylactic treatment. The few data available on the economic burden of CH come from retrospective studies
based on questionnaires, population surveys and medical insurance claims database. Although all these studies
showed an important economic burden, they provided different estimates depending on variability of CH
awareness and management, healthcare systems, available therapies and use of treatments according to different
guidelines.
Methods: This prospective study aimed to quantify the total direct and indirect cost of ECH and CCH over a cluster
period, both for the patient and for the National Health System (NHS), using data from subjects who consecutively
attended an Italian tertiary headache centre between January 1, 2018 and December 31, 2018.
Results: A total 108 patients (89 ECH, 19 CCH) were included. Mean attack frequency was 2.3 ± 1.4 per day. Mean
total cost of a CH bout was €4398 per patient and total cost of CCH was 5.4 times higher than ECH (€13,350 vs.
€2487, p < 0.001). Direct costs represented the 72.1% of total cost and were covered for the 94.8% by the NHS. The
costs for any item of expense were higher for CCH than for ECH (p < 0.001). Mean indirect costs for a CH bout
were €1226 per patient and were higher for CCH compared to ECH (€3.538 vs. €732), but the difference was not
significant. Days with reduced productive capacity impacted for the 64.6% of the total indirect costs. The analysis of
the impact CH on work showed that 27%% of patients felt that CH had limited their career, 40% had changed their
work pattern, 20% had changed their place of employment and 10% had lost a job due to the disease.
Conclusion: Our results provide a valuable estimate of the direct and indirect costs of ECH and CCH in the specific
setting of a tertiary headache centre and confirm the high economic impact of CH on both the NHS and patients.
Keywords: Cost of illness, Cluster headache, Chronic cluster headache, Episodic cluster headache, Burden of
disease, Resource utilization
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: andrea.negro@uniroma1.it
†Andrea Negro and Paolo Sciattella contributed equally to this work.
1Department of Clinical and Molecular Medicine, Sapienza University, Rome,
Italy
2Regional Referral Headache Centre, Sant’Andrea Hospital, Rome, Italy
Full list of author information is available at the end of the article
The Journal of Headache
                           and Pain
Negro et al. The Journal of Headache and Pain           (2020) 21:44 
https://doi.org/10.1186/s10194-020-01115-4
Introduction
Cluster headache (CH) is the most frequent of the so-
called trigemino-autonomic cephalgias (TACs) and is the
most severe of primary headaches. CH is characterized by
excruciating unilateral pain lasting from 15min to 3 h,
with attacks occurring every other day up to eight times a
day for weeks or months during active cluster periods,
followed by periods of remission. Attacks are accompan-
ied by a sense of restlessness or agitation and ipsilateral
cranial autonomic features common to all TACs, such as
conjunctival injection and/or lacrimation, nasal congestion
and/or rhinorrhea, eyelid oedema, forehead and facial
sweating, and miosis and/or ptosis [1]. The age of onset is
typically between 20 and 40 years with a 3-fold male pre-
ponderance. CH is relatively rare compared with other
primary headaches, as demonstrated by a meta-analysis of
15 studies in 10 countries that estimated a worldwide
lifetime-prevalence of around 1 per 1000 in all age groups
[2]. There are 2 types of CH: episodic CH (ECH) and
chronic CH (CCH). According to the third edition of the
International Classification of Headache Disorders
(ICHD3) [1], patients with ECH suffer from headache at-
tacks that occur in periods ranging from 7 days to 1 year,
separated by pain-free periods lasting at least 3months.
CH occurs in 85–90% of patients as episodic with an aver-
age bouts duration of 8.6 weeks [3]. The remaining 10–
15% of patients suffer from CCH), without such periods of
remission.
Almost a third of the patients with ECH at onset de-
velops CCH 10 years later and the same proportion of
patients with CCH at onset turns into episodic within
10 years [4]. Unfortunately, half of patients with CCH at
onset still have CCH after 20 years or more [4] and a
considerable proportion often resist pharmaceutical
treatments leading to refractory CCH as defined by the
European Headache Federation (EHF) [5].
The pathogenesis of CH is incompletely understood,
although evidence suggests that the trigeminovascular
system and neurogenic inflammation play important
roles and hypothalamic activation is suspected to be a
key factor in the generation of attacks [6]. Treatment
of CH is based exclusively on pharmacological mea-
sures and consists of two basic principles: symptom-
atic therapy taken at the time of an attack and
preventive treatment to suppress further attacks.
When a new cluster bout begins, both acute symp-
tomatic and preventive therapy should be initiated. In
addition to preventive medication, transitional therap-
ies (e.g., oral steroids and suboccipital steroid injec-
tions) are often used to achieve short-term symptom
improvement until the preventive drug dose can be
increased and becomes effective. This therapeutic ap-
proach is particularly suitable for those patients with
a high frequency of attacks.
CH has often been referred to as “suicide headache”
due to the excruciating pain of the attacks and although
these are periodic in most cases, the personal burden
can be considerable due to lifestyle restrictions during
the bouts, increased use of health care and the negative
impact on work [7]. The few data available on the eco-
nomic burden of CH come from retrospective studies
based on questionnaires, population surveys and medical
insurance claims database [8–10]. Although all these
studies showed an important economic burden, they
provided different estimates depending on variability of
CH awareness and management, healthcare systems,
available therapies and use of treatments according to
different guidelines.
Therefore, this study was conducted in a tertiary head-
ache centre to estimate the total cost (direct and indir-
ect) of treating ECH and CCH over a cluster period and
to determine the economic burden for patients and the
National Health System (NHS).
Methods
Study design
The study is a prospective and cross-sectional evaluation
of the direct and indirect costs of ECH and CCH, carried
out at the outpatient Regional Referral Headache Centre,
Department of Clinical and Molecular Medicine, Faculty
of Medicine and Psychology, Sapienza University of Rome.
The study population included all patients with CH
who consecutively attended our tertiary level headache
center between January 1, 2018 and December 31, 2018.
The headache diaries designed specifically for CH were
given to participants to record the amount and duration
of use (e.g., oxygen inhalation) of the prescribed acute,
preventive and oral transitional treatments. Headache
diaries were also used to record days off work and days
with reduced work efficiency. Patients’ electronic med-
ical records (EMRs) were used to collect further infor-
mation, such as the number of visits to our headache
centre, other specialist visits, diagnostic tests, therapeutic
procedures performed at our clinic (e.g. steroid subocci-
pital injections) and admissions to the emergency de-
partment (ED). Patients’ EMRs are updated at each visit
with information obtained from the patient and with
data extracted from the headache diary.
Inclusion criteria were: 1) diagnosis of CH (according
to ICHD3 [1]); 2) age ≥ 18 years at the time of enroll-
ment; 3) continuous treatment for the entire duration of
the cluster bout; and 4) complete compilation of the
headache diary reporting medication consumptions.
Data analysis
The data collected included demographic characteristics,
medical history of CH, number of specialist visits, num-
ber of diagnostic tests (e.g. electrocardiogram and brain
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magnetic resonance), medication consumption (acute,
transitional and preventive drugs) and number of ED ad-
missions. In Italy, ED visits are fully funded by the NHS,
while specialist visits, diagnostic tests, hospital thera-
peutic procedures and medications may be partially
funded by the NHS or fully paid by the patient. The use
of drugs has been quantified by analyzing patients’ head-
ache diary records. Similarly, indirect costs due to days
of absence from work and days with reduced work effi-
ciency were assessed analyzing the data recorded by par-
ticipants in their diaries.
Economic analysis
The costs have been estimated from both societal and
patient perspective. Intangible costs were not included
in this evaluation. The costs have been calculated for the
entire duration of a CH period. All costs are expressed
in Euros and adjusted for the year 2019. Estimates of
direct costs are the total of everything that has been paid
or reimbursed by the NHS plus payments of own pocket
money. Unit costs have been collected from publicly
available sources in the calendar year 2019. The Regional
Tariff Nomenclator for Outpatient Specialist Services
was considered for outpatient specialist services [11]
while each ED visit was considered to be €241 [12]. The
costs of the drugs have been estimated using the reim-
bursement price of the Regional Health System for the
classes of drugs charged to the NHS [13], while the costs
of classes of drugs partially charged to the NHS or to-
tally charged to the patient have been identified by a pri-
vate site for health care professionals.
In addition, indirect costs caused by disability have
been calculated according to the “cost of illness” meth-
odology among gainfully employed subjects, both full-
time and part-time [14]. The daily cost was calculated
from the societal perspective using average labor costs.
The cost of illness has been calculated by multiplying re-
source consumption and estimated prices.
Statistics
The demographic and clinical characteristics, the num-
ber of specialist visits, the number of diagnostic tests,
the consumption of drugs (reimbursed and not reim-
bursed by the NHS) and the number of ED visits have
been assessed in a descriptive way. The categorical data
were summarized by numbers and percentages, the con-
tinuous data by mean ± standard deviation (SD). The de-
scriptive statistics are presented as means ± SD. The
presence of statistically significant differences between
ECH and CCH patients was evaluated by Chi-square test
and Fisher exact test, when appropriate, for proportion,
Student’s T tests for normal distributions and Mann-
Whitney tests for non-normal distributions. All analyses
were performed using the SAS statistical package, ver-
sion 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Patients characteristics
The sample analyzed consisted of 108 patients, 9 (8.3%)
women and 99 (91.7%) men, aged between 22 and 76
years. Patient characteristics are shown in Table 1. The
average age of men was 44.1 ± 11.8 years and of women
was 36.2 ± 12.3 years. The age at onset of CH was 30 ±
11 years. According to the ICHD-III diagnostic criteria,
89 (82.4%) subjects had ECH and 19 (17.6%) had CCH.
On average, patients had 2.3 ± 1.4 attacks per day (CCH:
2.2 ± 1.7, ECH: 2.4 ± 1.3) with a range from 0.4 (3 per
week) to 6 attacks per day. The mean duration of bouts
in the total population was 14.8 ± 17.9 weeks with a
minimum of 1 week to a maximum of 12months. The
mean duration of bouts among ECH patients was 6.8 ±
5.1 weeks with a minimum of 1 week to a maximum of
6 months.
Specialist visits
Patients enrolled in the study consulted our outpatient
headache centre with an average number of 3.0 ± 1.9 visits
(range 1–9) during the CH period (Table 2). The average
number of headache visits was higher for CCH (6.7 ± 1.5;
range: 4–9) than ECH (2.2 ± 0.7, range 1–5; p < 0.0001).
A cardiologist was consulted by 13 (68.4%) CCH patients
and by 23 (11.2%) ECH patients (p < 0.0001).
The mean cost of specialist visits was €169 ± €114
(range: €53–527) per patient, covered by NHS for the
39%, and was significantly higher for CCH (€391 ± €77)
than ECH (€122 ± €42; p < 0.0001) (Table 3).
Diagnostic tests
The use of at least one diagnostic during the bout in-
volved 71 (65.7%) patients (Table 2). Seventy-one
(65.7%) patients received at least one electrocardiogram
(ECG). Higher proportion of CCH patients had pre-
scribed an ECG compared to ECH patients (94.7.% vs.
59.6%; p 0.002). The mean number of ECG per patient
was higher for CCH (2.5 ± 1.2) than ECH (0.6 ± 0.7;
p < 0.0001). Thirty-seven (34.3%) patients underwent to
brain magnetic resonance imaging (MRI). Higher pro-
portion of CCH patients received a prescription for a
brain MRI compared to ECH patients (84.2% vs. 23.6%;
p < 0.0001). The mean number of brain MRI per patient
was higher for CCH (0.8 ± 0.4) than ECH (0.2 ± 0.4;
p < 0.0001).
The diagnostic tests had an average cost per patient of
€204 ± €237 (range: €0–691), covered by the NHS for
82.4% (€168 ± €200). The cost was significantly higher
for CCH (€520 ± € 188) than ECH (€137 ± €187;
p < 0.0001) (Table 3).
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Table 1 Patients characteristics: demographic, occupational and medical
Diagnosis ECH
(n = 89)
CCH
(n = 19)
Total
(n = 108)
p-value
Men, n. (%) 81 (91) 18 (95) 99 (92) N.S.
Women, n. (%) 8 (9) 1 (5) 9 (8)
Age, years 43.4 ± 12.5
(22–76)
43.8 ± 9.5
(23–62)
43.4 ± 12.0
(22–76)
N.S.
Level of education, n. (%)
Primary 4 (4) 0 (0) 4 (4) N.S.
Secondary 35 (39) 7 (37) 42 (39)
Degree 50 (56) 12 (63) 62 (57)
Gross annual income (€)
0 21 (24) 7 (37) 28 (26) N.S.
< 10,000 19 (21) 5 (26) 24 (22)
10,000 - 24,999 32 (36) 3 (16) 35 (32)
≥ 25,000 17 (19) 4 (21) 21 (19)
Employment status, n. (%)
Employed (full-time) 48 (53.9) 7 (36.8) 55 (50.9) 0.016
Employed (part-time) 20 (22.5) 5 (26.3) 25 (23.1)
Retired 6 (6.7) 0 (0) 6 (5.6)
Unemployed 7 (7.9) 7 (36.8) 14 (13)
Housewife/student 8 (9) 0 (0) 8 (7.4)
Age at onset, years 30.5 ± 11.4
(14–64)
29.9 ± 10.2
(18–56)
30.4 ± 11.2
(14–64)
N.S.
Duration of disease, years 12.8 ± 10.0
(0–37)
13.9 ± 7.1
(0–30)
13,0 ± 9.5
(0–37)
N.S.
Diagnostic delay, years 4.2 ± 3.6
(0–16)
2.7 ± 1.8
(0–7)
3.9 ± 3.4
(0–16)
N.S.
New CH diagnosis, n. (%) 30 (33.7) 1 (5.3) 31 (28.7) 0.012
Frequency of attacks, per day 2.4 ± 1.3
(0.4–5.0)
2.2 ± 1.7
(0.4–6.0)
2.3 ± 1.4
(0.4–6.0)
N.S.
Duration of attack without treatment, min. 64.3 ± 32.2
(20–150)
79.7 ± 31.3
(35–150)
67.0 ± 32.4
(20–150)
0.30
Duration of attack with treatment, min. 13.7 ± 5.6
(5–40)
13.5 ± 4.7
(8–25)
13.6 ± 5.4
(5–40)
N.S.
Duration of bouts, weeks 6.8 ± 5.1
(1–25)
52.0 ± 0
(52)
14.8 ± 17.9
(1–52)
< 0.0001
Laterality, left, n. (%) 46 (52) 8 (42) 54 (50 N.S.
CH symptoms, n. (%)
conjunctival injection and/or lacrimation 45 (50.6) 12 (63.2) 57 (52.8) N.S.
nasal congestion and/or rhinorrhoea 54 (60.7) 8 (42.1) 62 (57.4) N.S.
eyelid oedema 66 (74.2) 15 (78.9) 81 (75) N.S.
forehead and facial sweating 41 (46.1) 8 (42.1) 49 (45.4) N.S.
miosis and/or ptosis 40 (44.9) 11 (57.9) 51 (47.2) N.S.
sense of restlessness or agitation 65 (73) 14 (73.7) 79 (73.1) N.S.
CCH Chronic cluster headache, ECH Episodic cluster headache
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Table 2 Healthcare resource use
Diagnosis ECH
(n = 89)
CCH
(n = 19)
Total
(n = 108)
p-value
Headache centre visits, n. 2.2 ± 0.7 (1–5) 6.7 ± 1.5 (4–9) 3.0 ± 1.9 (1–9) < 0.0001
Cardiology visits, n. (%) patients 10 (11.2) 13 (68.4) 23 (21.3) < 0.0001
ED visits, n. (%) patients 14 (15.7) 11 (57.9) 25 (23.1) < 0.0001
ED visits, n. per patient 0.2 ± 0.6 (0–3) 0.7 ± 0.7 (0–2) 0.3 ± 0.6 (0–3) 0.000
ECG, n. (%) patients 53 (59.6) 18 (94.7) 71 (65.7) 0.002
ECG, n. per patient 0.6 ± 0.7 (0–3) 2.5 ± 1.2 (0–4) 0.9 ± 1.1 (0–4) < 0.0001
Brain MRI, n. (%) patients 21 (23.6) 16 (84.2) 37 (34.3) < 0.0001
Brain MRI, n. per patient 0.2 ± 0.4 (0–1) 0.8 ± 0.4 (0–1) 0.3 ± 0.5 (0–1) < 0.0001
Acute medications, n. (%)
Sumatriptan 6 mg 56 (62.9) 17 (89.5) 73 (67.6) 0.030
Zolmitriptan 5 mg 19 (21.3) 1 (5.3) 20 (18.5) N.S.
Oxygen 71 (79.8) 19 (100) 90 (83.3) 0.038
Combinations 57 (64) 18 (94.7) 75 (69.4) 0.007
Transitional treatments, n. (%)
Oral corticosteroids 29 (32.6) 0 (0) 29 (26.9) 0.002
G.O.N. block 8 (9) 15 (78.9) 23 (21.3) < 0.0001
Preventive medications, n. (%)
Verapamil 62 (69.7) 15 (78.9) 77 (71.3) N.S.
Topiramate 30 (33.7) 11 (57.9) 41 (38) 0.048
Combinations 51 (57.3) 18 (94.7) 69 (63.9) 0.001
Nutraceutics, n. (%)
Melatonin 31 (34.8) 17 (89.5) 48 (44.4) < 0.0001
CCH Chronic cluster headache, ECH Episodic cluster headache, ECG Electrocardiogram, ED Emergency department, GON Great occipital nerve, MRI Magnetic
resonance imaging
Table 3 Direct costs per CH bout
Diagnosis EEC (n = 89) CCH (n = 19) Total (n = 108) p-value
NHS PRI NHS PRI NHS PRI
Specialist visits €48 ± €16
(21–103)
€74 ± €25
(32–160)
€153 ± €30
(103–207)
€237 ± €47
(160–320)
€66 ± €45
(21–207)
€103 ± €69 (32–320) < 0.0001
ED visit €51 ± €133
(0–723)
– €165 ± €162
(0–482)
– €71 ± €145
(0–723)
– 0.000
Diagnostic tests €113 ± €161
(0–506)
€24 ± €27
(0–111)
€426 ± €156
(0–558)
€94 ± €34
(0–133)
€168 ± €200
(0–558)
€36 ± €39
(0–133)
< 0.0001
Acute medications €1387 ± €1938
(14–8724)
– €8314 ± €6822
(362–25,024)
– €2606 ± €4236
(14–25,024)
– < 0.0001
Transitional treatments €7 ± €15
(0–60)
€3 ± €9
(0–32)
€41 ± €22
(0–52)
€25 ± €13
(0–32)
€13 ± €21
(0–60)
€7 ± €13
(0–32)
< 0.0001
Preventive medications €40 ± €58
(0–371)
€8 ± €15
(0–60)
€275 ± €85
(153–445)
€82 ± €29
(0–91)
€81 ± €110
(0–445)
€21 ± €33
(0–91)
< 0.0001
Total €1647 ± €2064
(34–9629)
€109 ± €60
(32–299)
€9374 ± €6898
(1382-26,147)
€438 ± €71
(315–554)
€3006 ± €4500
(34–26,147)
€166 ± €140
(32–554)
< 0.0001
€1755 ± €2110
(66–9927)
€9812 ± €6932
(1755-26,626)
€3173 ± €4609
(66–26,626)
< 0.0001
CCH Chronic cluster headache, ECH Episodic cluster headache, ED Emergency department, NHS National health system, PRI Private cost
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ED visits
During a bout, 25 (23.1%) of 108 patients entered the
ED because of CH attack (Table 2). Higher proportion
of CCH patients visited the ED compared to ECH pa-
tients (57.9% vs. 15.7%; p < 0.0001). The average number
of ED visits per patient was higher for CCH (0.7 ± 0.7,
range 0–2) than ECH (0.2 ± 0.6; range: 0–3; p < 0.0001).
The mean annual cost for the NHS relating to ED
visits was €71 ± €145 (range: €0–723) per patient and
the cost was higher for CCH (€165 ± €162) than ECH
(€51 ± €133; p < 0.0001) (Table 3).
Medications consumption
The allocation of intake of attack-aborting treatment
and drugs is shown in Table 2. Regarding acute medica-
tions, CCH patients used significantly more sumatriptan
6 mg and oxygen than EEC patients (p = 0.030 and p =
0.038, respectively), while the use of zolmitriptan 5mg
did not differ between the two groups. Higher propor-
tion of CCH patients used more than one medication to
treat the headache (p = 0.007). Regarding preventive
medications, CCH patients used significantly more topir-
amate than ECH patients (p = 0.048), while the use of
verapamil did not differ between the two groups. Higher
proportion of CCH patients used a combination of two
drugs as prevention (p = 0.001). Similarly, the use of
transitional treatments, both oral corticosteroids and
steroid suboccipital injections, was significantly higher
for CCH than ECH patients (p = 0.002 and p < 0.0001,
respectively). CCH patients also used more melatonin
than ECH patients (p < 0.0001).
The mean cost of acute medications for CH bout was
€2606 ± €4236 (range: €14–25,024) per patient and was
significantly higher for CCH (€8314 ± €6822) than ECH
(€1387 ± €1938; p < 0.0001) (Table 3). The mean cost of
preventive medications for CH bout was €102 ± €138
(range: €0–537) per patient and was significantly higher
for CCH (€357 ± €74) than ECH (€48 ± €70; p < 0.0001).
The mean cost of transitional treatments for CH bout
was €20 ± €34 (range: €0–92) per patient and was signifi-
cantly higher for CCH (€66 ± €35) than ECH (€10 ± €24;
p < 0.0001).
Impact on work
The mean number of days off work within the bout due
to CH was nearly 7 days. Statistically the number of ab-
sence days due to headache was significantly larger
among CCH patients (15.2 ± 11.8) than ECH patients
(5.6 ± 7.9; p < .0001) (Table 4). On the contrary, the pro-
portion of days off work respect to the bout duration
was higher for ECH patients than CCH patients (10.3%
vs. 4.2%, respectively; p < .0001), due to the longer dur-
ation of CCH bout. Overall, CH was responsible of
nearly 16 days of work with reduced capacity. The im-
pact of CCH was higher than that of ECH (46.3 ± 72.2
vs. 10.8 ± 14.0 days, respectively), but the difference was
not significant. The reduction of productive capacity at
work is shown in Fig. 1. The reports of work changes
due to CH are shown in Fig. 2.
The mean cost of absences from work for CH bout
was €434 ± €952 (range: €0–5603) per patient and was
higher for CCH (€879 ± €1694) then ECH (€339 ± €680),
but the difference was not significant (Table 4). The
mean cost attributed to days with reduced productive
capacity for CH bout was €792 ± €3541 (range: €0–29,
501) per patient and was higher for CCH (€2659 ±
€7818) then ECH (€393 ± €1352), but the difference was
not significant.
Direct costs
The mean direct costs of a CH bout were €3173 ± €4609
(range: €66–26,626) per patient and was covered for the
Table 4 Impact on work and indirect costs
Diagnosis ECH
(n = 77)
CCH
(n = 12)
Total
(n = 89)
p-value
Days off work (or study), n. 5.6 ± 7.9
(1–45)
15.2 ± 11.8
(5–45)
6.9 ± 9.1
(1–45)
< 0.0001
Days off work (or study) / bout duration, % 10.3 ± 6.4
(2–31)
4.2 ± 3.2
(1–12)
9.5 ± 6.4
(1–31)
0.000
Days with reduced productive capacity, n. 10.8 ± 14.0
(0–70)
46.3 ± 72.2
(0–220)
15.6 ± 31.3
(0–220)
N.S.
Days with reduced productive capacity / bout duration, % 18.1 ± 16.3
(0–52)
12.7 ± 19.8
(0–60)
17.4 ± 16.8
(0–60)
N.S.
Days off work (per bout) €339 ± €680
(0–3678)
€879 ± €1694
(0–5603)
€434 ± €952
(0–5603)
N.S.
Days with reduced productive capacity (per bout) €393 ± €1352
(0–11,648)
€2659 ± €7818
(0–29,501)
€792 ± €3541
(0–29,501)
N.S.
Total (per bout) €732 ± €1.928
(0–15,326)
€3.538 ± €9420
(0–34,865)
€1226 ± €4374
(0–34,865)
N.S.
CCH Chronic cluster headache, ECH Episodic cluster headache
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94.8% (€3006) by the NHS (Table 3). The main item of
expenditure was represented by treatments that
accounted for 86% (€2728), followed by diagnostic tests
for 6% (€204), specialist visits for 5% (€169) and ED
visits for 3% (€71) (Fig. 3). The mean direct costs of a
CH bout were significantly higher for CCH (€9812 ±
€6932) than ECH (€1755 ± €2110; p < 0.0001). There
were small differences between the impact of the differ-
ent expenditure items between CCH and ECH: 89% vs.
82% for treatments, 5% vs. 8% for diagnostic tests, 4% vs.
7% for specialist visits, and 2% vs. 3% for ED visits,
respectively.
Indirect costs
The mean indirect costs for a CH bout were €1226 ±
€4374 (€0–34,865) per patient and were higher for CCH
(€3.538 ± €9420) than ECH (€732 ± €1928), but the dif-
ference was not significant (Table 4). Days with reduced
production capacity impacted for the 64.6% (€792) of
the total indirect costs.
Analysis of total costs
The mean total costs (direct + indirect) for a CH bout
were €4398 ± €7724 (66–51,281) per patient and the dir-
ect costs accounted for 72.1% (€3173) (Fig. 4). The total
cost of CCH (€13,350 ± €13,991; range 2157-51,281) was
5.4 times higher than ECH (€2487 ± €3394; range 66–20,
697; p < 0.001) and the difference in the total average
costs of a CH bout between CCH and ECH was €10,863.
The impact of direct costs on total expenditure was
higher for CCH than ECH (73.5% vs. 70.6%), but the dif-
ference was not significant.
Fig. 1 Reported work efficiency during a cluster period
Fig. 2 Reports of work changes due to cluster headache. Legend: * p < 0.0001; # p = 0.022
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Fig. 3 Direct costs per cluster headache patient
Fig. 4 Total costs per cluster headache patient
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Discussion
Our study provides a detailed quantification of the mean
direct and indirect costs associated with ECH and CCH
(assessed with the ICHD-3 [1]) in a large population of
patients attending an Italian tertiary level headache
centre. Direct costs accounted for nearly three fourth of
the total costs and 94.8% (€3006) was funded by the
NHS while patients had an annual personal expenditure
of €167 as a contribution for specialist visits, diagnostic
tests, and medications. The total cost of CCH was 5.4
times higher than that of ECH. The cost charged to the
NHS was €9374 for CCH and €1647 for ECH, while the
cost for the patient was €438 for CCH and €109 for
ECH. The costs for any item of expense were higher for
CCH than for ECH. In fact, compared to ECH patients,
CCH patients made 3-times more specialist visits and
ED visits and 4-times more ECG and brain MRI. Overall,
these data indicate that CCH patients have an increased
need for follow-up due to the higher severity of the con-
dition and the higher dose of preventive medications.
Only one other European study has recently assessed
the cost of CH in our same setting of a headache centre.
In 2010, Gaul et al. [8] retrospectively assessed the direct
and indirect costs of CH diagnosed according to the sec-
ond edition of the ICHD [15] in a sample of 179 patients
(72 CCH, 107 CCH) attending a German headache
centre. Unfortunately, important differences in the
methodology and in the voices of expenditure consid-
ered between their and our study may limit a proper
comparison of the results. The authors assessed the cost
of a 6-month period while we prospectively evaluated
the costs related to the duration of a CH bout. More-
over, Gaul et al. included the costs related to some
drugs (e.g. lithium, gabapentin, valproate), specialist
visits (e.g. pain specialist, osteopath, neurosurgeon) and
procedures (e.g. physiotherapy, massage and manual
therapy, acupuncture, occipital nerve stimulation) that
we did not use in our patients [8]. In their study,
hospitalization for headache treatment (€24,086), re-
habilitation (€18,556) and the costs of surgery and
hospitalization for occipital nerve stimulation (€40,578)
had an important impact on costs estimates. They esti-
mated the total costs of a 6-month period in €10,985 per
patient with CCH and €2583 per patient with ECH.
As regard to indirect costs, in our study they repre-
sented 27.9% of the total cost of CH bout and, as ex-
pected, they were higher for CCH than ECH (€3.538 vs.
€732), although not significantly. Days with reduced pro-
duction capacity impacted for 64.6% of total indirect
costs. CCH patients made significantly more absences
from work than ECH patients (15.2 ± 11.8 vs. 5.6 ± 7.9)
and, although the cost of days off work was higher for
CCH then ECH (€879 vs. €339), the difference was not
significant. A previous analysis conducted by Jensen
et al. on 85 CH patients (20% with CCH) in a Danish
headache centre showed an important impact on work
[9]. In detail, 39% of patients felt that CH had limited
their career, 27% had changed their work pattern, 15%
had changed their place of employment and 16% had
lost a job due to the disease. In our study, we investi-
gated the same aspects and found similar results (27%,
40%, 20% and 10%, respectively). In addition, we also an-
alyzed the impact of the two forms of CH separately,
showing a significantly higher burden in association with
CCH. In detail, the ratio of the percentages of CCH and
ECH patients for limitation of their career was 5.7:1, for
the change of work pattern was 1.8:1, for the change of
place of employment was 5.6:1 and for job loss was 12.4:
1. When asked to quantify their work efficiency, 58% of
ECH patients and 42% of CCH patients felt no or very
few restrictions in their work efficiency, either because
they had very effective and reliable treatment for the
headaches or because most attacks occurred during
night time and did not affect their daytime condition.
Unexpectedly, we have not observed any differences in
the severe reduction in production capacity between
CCH and ECH.
Methodological considerations
There are several important limitations that need to be
considered when interpreting these results. Our study
was conducted on a sample of patients attending a ter-
tiary headache centre and our results may therefore not
be representative of CH patients in the general popula-
tion as specialist clinics usually see most disabled pa-
tients with a history of treatment failures and treatment
attempts by general practitioners. However, most previ-
ous studies of CH have been conducted on patients from
headache clinics. In addition, the proportion between
ECH and CCH (82.4% and 17.6%, respectively) and dur-
ation of the disease (13 years) were similar to previous
epidemiological series and our results can therefore be
comparable to both studies conducted in the same set-
ting of a headache clinic [9] and most other population-
based studies [16, 17]. The higher proportion of CCH
patients in a tertiary headache centre compared than in
the general population may result in more people refrac-
tory to conventional treatment. In our population, 15 of
the 19 CCH patients had refractory CCH according to
the definition proposed by EHF [5]. Refractory patients
use more healthcare resources and more acute treat-
ments, and because of their higher and permanent
disability compared to other patients, they show a
greater work impairment leading to increased indirect
costs. Unfortunately, the detailed analysis of this sub-
group of patients has not been made. However, we be-
lieve that demographic and clinical CH characteristics of
our patients’ sample are those typical of a cohort of CH
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and, therefore, our population may be comparable to
other clinical populations [8, 17].
With regard to the cost analysis, we have calculated
only the direct and indirect costs closely related to CH,
but not the cost of conditions that are comorbid or sec-
ondary to CH or to its treatment, which can have a
strong economic impact on the management of CH.
Taking those aspects into account, the cost of headache
would be even higher. Our economic analyses have been
designed to capture only the costs associated with a CH
bout, from the day of the onset until the end of the
active period with suspension of the pharmacological
treatment and final follow-up at our headache centre.
Consequently, we have not assessed the cost of the refer-
ring general practitioners, which in Italy is entirely
covered by the NHS. Likewise, we have not assessed the
costs of physicians, resident doctors and nurses (fully
covered by the NHS) or the costs of medications (e.g.
lithium) and procedures (e.g. surgery, transcutaneous
nerve stimulators and acupuncture) which for various
reasons are not routinely used in our clinic. A further
limitation of our economic analysis is that we have not
calculated the indirect costs due to the impact of CH on
family life.
An advantage of this study is the high validity of the
headache diagnosis, which was assessed by a headache
expert. In contrast, studies in which patients were identi-
fied by administrative claims as opposed to medical re-
cords showed the potential for misclassification of
migraine or chronic migraine as CH [10]. In addition,
administrative claims data may be subject to data encod-
ing limitations and data entry error and, in some coun-
tries, may be limited only to individuals with employee
health insurance or supplemental insurance, so that they
cannot be representative of all CH patients.
To our knowledge, this study is the first to establish
the diagnosis according to the most recent and currently
used third version of the ICHD criteria, which presents
important differences form the second edition used in
previous studies [15].
However, the main advantage of this study is the adop-
tion of a prospective design that has never before been
used before for “cost of illness” studies for CH. In fact,
recall bias is usually a major problem in retrospective
clinical studies, even for highly debilitating diseases such
as CH, for which one might expect most patients to be
able to remember their attacks accurately. However, re-
call specific data on drug consumption and days off
work or with reduced productivity is usually more unre-
liable. Instead, we have carried out a detailed analysis by
collecting information on every single attack during the
CH period and calculating in detail the changes in drug
use. This method provides more reliable data on health
resource utilization than other studies that have
calculated the number of attacks by multiplying the fre-
quency of attacks per day by the duration of the CH
bout [8].
Conclusions
Our results provide a valuable estimate of the direct and
indirect costs of patients with ECH and CCH in the spe-
cific setting of a tertiary level headache centre and con-
firm the high economic impact of CH on both the NHS
and patients. CCH Patients had more visits, diagnostic
tests and drug use than patients with ECH, which led to
a total cost of 5.4 times that of ECH.
Cost of illness studies become obsolete due to chan-
ging healthcare systems and new treatments become
available. Governments and decision-makers should
strongly support these investigations to reveal the true
economic and social impact of this devastating pain dis-
ease, particularly when it is chronic.
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